Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections
18 mai 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese...
China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
13 mai 2020 09h39 HE
|
Zai Lab Limited
Optune is the first innovative treatment for glioblastoma approved in China in over 15 years A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to...
Zai Lab Announces NDA for Omadacycline Granted Priority Review by China’s NMPA
06 mai 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI, China, and SAN FRANCISCO, May 06, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced that the Center for...
Zai Lab Announces Upcoming Participation in the BofA Securities 2020 Health Care Conference
30 avr. 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI, China and SAN FRANCISCO, April 30, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today...
Zai Lab Announces China’s NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment
16 avr. 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI, China, and SAN FRANCISCO, April 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
08 avr. 2020 06h00 HE
|
Zai Lab Limited
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau Collaboration will also support enrollment of regional patients...
Zai Lab Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Updates
19 mars 2020 07h30 HE
|
Zai Lab Limited
-- Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT SHANGHAI, China and SAN FRANCISCO, March 19, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based...
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
16 mars 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI, China and SAN FRANCISCO, March 16, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced...
Zai Lab to Announce Financial Results for the Full Year Ended December 31, 2019 and Corporate Updates on March 19, 2020
05 mars 2020 07h30 HE
|
Zai Lab Limited
-- Company to host Conference Call and Webcast on March 19, 2020 at 8:30 a.m. ET SHANGHAI, China and SAN FRANCISCO, March 05, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and...
Zai Lab Announces Upcoming Participation at February Conferences
11 févr. 2020 07h30 HE
|
Zai Lab Limited
SHANGHAI, China and SAN FRANCISCO, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (“Zai Lab”) (NASDAQ: ZLAB), a China and U.S.-based innovative commercial-stage biopharmaceutical company, today...